LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced record-breaking financial results for 2024, driven by robust ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

We maintain our fair value estimate of $187 per share. Xywav (for excessive daytime sleepiness), Epidiolex (for childhood epilepsy), and Rylaze (for leukemia) have continued to be Jazz’s primary ...

The Pennsylvania-based drugmaker expects between $820 million and $860 million this year from WAKIX, as it pushes its ...

An expert discusses the significance of low-sodium oxybate for patients with narcolepsy patients with and cardiovascular disease and compares the diagnostic criteria and clinical presentations of ...

The main growth driver for Alkermes going forward will be ALKS 2680. Read why I maintain my buy rating on ALKS stock.

"We’re delighted to welcome Kevin to Avadel – he’s a great addition to our team with the deep experience to help us drive success at this important time," said Greg Divis, Chief Executive Officer of ...

Hundreds of children with severe epilepsy will be able to benefit from a groundbreaking new treatment on the NHS that could significantly reduce their seizures, providing new hope for them and their ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Harmony Biosciences Holdings said the Food and Drug Administration has turned away its application seeking expanded approval of its Wakix narcolepsy drug for the treatment of excessive daytime ...